Here we present a series of studies conducted by our group (Fig 1) and review the literature. Methods: We first determine whether certain serum miRNAs tested by qRT-PCR could represent potential diagnostic and prognostic

biomarkers for PDAC on 2010. Then the value of such miRNAs compared with serum CA19-9 was evaluated. We used serum samples to screen the differentially expressed serum miRNAs with Illumina sequencing by synthesis technology using pooled selleck chemicals llc serum samples followed by validation of a large number of samples arranged in multiple stages. Finally, the role of PDAC-specific miRNA was also studied by using transfection and animal model. Results: Of the serum miRNAs detected, miR-21, miR-155 and miR-196a were identified as differentially expressed in PDAC and control groups (chronic pancreatitis or normal). Selleck FK506 Furthermore, serum miR-196a expression level was found to have a potential value in predicting median survival time of PDAC

patients. The combination of miR-16, miR-196a and CA19-9 was more effective for discriminating PDAC from normal (sensitivity 92.0%; specificity 95.6%) compared with CA19-9 alone. Most significantly, the combination was effective at identification of tumors in Stage 1 (85.2%). A 7 miRNA – based biomarker can serve as a novel noninvasive approach for PDAC diagnosis and prognosis. Mir-196a was found to modulate PDAC progression via its target gene of inhibitor of growth 5 (ING5). Conclusion: Circulating miRNAs show promising value in diagnosis of PDAC. The origin and their roles on PDAC formation and invasion warrant further studies. Key Word(s): 1. pancreatic cancer; 2. miRNA; Presenting Author: RAJESH GUPTA Additional Authors: SUNIL SHENVI, YELLAKANTIRAGHAVENDRA medchemexpress BABU, PRASANNA C, SURINDER RANA, DEEPAK BHASIN, MANDEEP KANG, RAKESH KAPOOR Corresponding Author: RAJESH GUPTA Affiliations: PGIMER Objective: Despite advances in surgery and perioperative care that have resulted in markedly reduced postoperative mortality after pancreaticoduodenectomy(PD), the median survival for pancreatic cancer patients has changed minimally over the past two decades. Apart from SMA margin and Neoadjuvant

chemotherapy which have effect on long term survival of patients; reducing early mortalityfurthur following PD can also lead to improved results. Present study analysis the reasons and outcome for early mortality following PD. Methods: We retrospectively reviewed details of patients undergoing pancreatico-duodenectomy between January 2002 and Dec 2011 at Division of Surgical Gastroenterology, PGIMER, Chandigarh. A total of 101 patients underwent pancreaticoduodenectomy. Indications being Carcinoma head of pancreas/Periampullary carcinoma in 81, PNET in 11, chronic pancreatits in 6, duodenal GIST in 1, adenoma with high grade dysplasia in 2 patients. Results: There were 60 male patients. Mean age was 52±12.9 SEM (Range 25-78 years).Mean post op stay was 13.8days±6.5 SEM.